Amylyx (AMLX) CMO Camille Bedrosian Receives 22,807-Share Award

What Happened
Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals (AMLX), was awarded 22,807 shares that vested on August 18, 2026. The Form 4 reports the shares as acquired at $0.00 (total reported value $0), because these shares were issued upon the vesting of previously granted performance share units (PSUs).

Key Details

• Transaction date: August 18, 2026; Form 4 filed August 20, 2026 (timely filing).
• Transaction type: Award/Acquisition (code A) — 22,807 shares acquired at $0.00.
• Shares owned after transaction: Not specified in the summary provided.
• Footnote: The shares were represented by performance share units that vested after certain performance metrics were met (per filing footnote F1).
• No selling or open-market purchase involved; this was the vesting/issuance of compensation-related equity.

Context
This was a compensation-related issuance (vested PSUs converting to common shares), not an open-market trade. Such awards reflect company pay practices and the achievement of performance targets; they do not directly signal an insider buying or selling stock in the market.